Given its safety in phase I and II clinical trials, the rationale is to prevent severe forms and long-term disease [35]; hence, our result showing a two-fold increase in LIF highlights the rationale of using recombinant LIF in COVID-19 patients. This evidence concerns the gene LIF and COVID-19.